Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Valeant Pharmaceuticals

News

Valeant Pharma Raises Offer For Salix Pharma: What it Means For Mutual Fund Investors (VRX, SLXP)

Shauna O'Brien Mar 16, 2015



Inside the Deal


In the previous deal, Valeant offered to acquire the company for $158 per share, or $14.5 billion. The offer was increased after Endo International (ENDP) expressed interest in acquiring Salix for $175 per share, or $11 billion.

The adjusted deal has been approved by the Boards of Directors of both companies.


Valeant And It’s M&A Strategy


Last year, Valeant’s deal to acquire Allergan (AGN) fell through, and since then, VRX has been seeking alternative deals.


Mutual Funds to Watch



The Bottom Line


If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.

Download Our Free Report

Why 30 trillion is invested in mutual funds book